N.Z. Tamiflu Stocks Feared Ineffective Against New Flu Strain
This article was originally published in PharmAsia News
Executive Summary
New Zealand authorities fear the nation's stockpile of Roche's Tamiflu (oseltamivir) retroviral against influenza may not be useful due to a rapid spread of drug-resistant forms of the virus. In addition, 103 of the 1,229 treatment courses the government bought already have expired. World Health Organization tests showed a third of those with the H1N1 flu strain in South Africa had a drug-resistant form, even though only one of the 107 had been taking Tamiflu. Similar tests in 12 other countries through Aug. 20 also found H274Y mutations resistant to the drug. (Click here for more
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.